About This Video
MYND Life Sciences Inc. is a public company listed on the Canadian Securities Exchange stock market under the symbol MYND.
Mynd is a life sciences based neuro-pharmaceutical drug development company advancing medicines that leverage psychedelic compounds. Their mission is to further their existing research and patents linking depression and inflammation at the genetic and cellular level to develop pharmaceutical treatments.
Learn more about MYND Life Sciences Inc. at https://thecse.com/en/listings/life-sciences/mynd-life-sciences-inc
Subscribe for more great CSE insights and interviews here: https://go.thecse.com/CSETV-Subscribe
STAY CONNECTED WITH THE CSE
=============================
- PODCAST: https://blog.thecse.com/cse-podcasts/
- INSTAGRAM: https://www.instagram.com/canadianexchange/
- LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange
- FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/
- TWITTER: https://twitter.com/CSE_News
- BLOG: https://blog.thecse.com/
- WEBSITE: https://thecse.com/
- MAGAZINE: https://issuu.com/thecse/docs
Read the TranscriptAuto-generated by YouTube; names and terms may be misspelled.
hi welcome to not newly listed more of an update with with the canadian securities exchange i'm your host barrington miller director of issuer engagement and today i'm here with dr lyle oberg ceo of mind life sciences that is mind m training on the csc welcome to the show thank you very much barrington it's great to be here let's let's start off because as i mentioned
earlier this is not a newly listed clip you have been listed with the with the csc but this is more of an update but for those who are just joining us and who may not know what does mind life sciences do mind life science is currently doing research into many of the psychedelics but psilocybin in particular we have identified what is the so-called trigger gene that turns off inflammation
and what we found is that psilocybin in particular is a very strong anti-inflammatory and actually shuts off that gene so what that means literally is that inflammatory diseases by elevating this particular gene level which psilocybin does it actually turns off the inflammatory process inflammatory processes are good you know when you cut your hand and you see redness around it and things like that that's good that's the inflammatory
process working to heal where inflammatory processes are bad is when they don't shut off is when they continue on and this is where you get autoimmune diseases where the body in essence attacks itself and for contextually in 2021 probably the best example of a what is called a cytokine storm which is a really bad inflammatory state is covered 19. so covin-19 doesn't kill you because there's too many viruses in the body
what happens is copen 19 actually turns on the body to such a degree that the inflammatory response your own body kills your organs and ends up killing you and obviously that's in the worst case scenario but literally that's what what happens and what our research is showing is that we can actually shut that inflammatory process off and in response to your question yes it does come back on
but we can shut it off at times when it's extremely high and i'll take it one step further if you can't if i may psilocybin has for a long time been known to be hallucinogenic right so that's a very important trait of psilocybin because it shows that it gets into the brain like not a lot of drugs get into the brain there's a thing called the blood-brain barrier
which basically keeps a lot of stuff out from the brain but we know that psilocybin is getting in so if you if you pair that with the current thinking that depression is a neuro inflammatory disease and if for those of you who want to do research if you take a look at neural inflammation and depression that's basically the prevailing theory about what happens with depression well what we've seen
is that psilocybin through its anti-inflammatory properties can actually stop that depression and if you think about it it's really consistent with what has been shown anecdotally where people take a you know a large dose of psilocybin and they get better for three or four months right okay well that isn't going to say you know that isn't going to stop five years of bad memories and things like that it's you know one dose simply isn't
going to do that so it's very consistent with all that and that's what we've discovered and then we went one step further and that one step further is we actually are developing and we're kind of 75 percent of the way there of developing a biomarker that actually measures this it actually measures the level of that gene so what we have the ability to do is actually predict when depression is
going to get better when depression is going to get worse and when you have depression so that's a very very powerful tool because up until now its depression diagnosis is made simply by symptomatology and not by the objective test well doctor this is this is truly fascinating i you know i i just don't do these updates for our our audience i'm a little bit selfish and i'm doing it for me too
so those are two massive massive areas that your company is undergoing research and you know providing just better better quality of life in the future now again for people that are listening we aren't we aren't necessarily endorsing at the cse but we are learning and this is what one of our companies are doing and it is it is cool as heck so i i guess there's a lot of there is a
lot of talk and a lot of buzziness around psychedelics and psilocybin and i guess i want to know what your differentiator is and and how people can see through the haze and the fog of all these companies that are out there and i mean there's so many different tiers and levels and and areas because it's such a wide topic but i mean you're you're in research in
research and development what's your differentiator well i guess first of all what i i want to say is that a lot of research into psychedelics is being done you know not necessarily in universities or not necessarily in universities that are top tier universities our research is being done at ubc and for canadians obviously that's the university of british columbia we're working out of the michael smith laboratory
michael smith was a nobel prize laureate and our lead researcher was the first person that he hired so he's been working out of that laboratory for 30 years so this is not a fly by night type of research this is very solid progressive research where we go from a to b to c to d and that's critically important because if you want to get a drug approved by the fda which will bring it
mainstream you have to do that you can't simply put forward anecdotal cases and ex unless they're you know the fda can do it if they're truly exceptional and truly overwhelming but the rarity of that is is quite astounding so what we're doing is following through we discovered how the drugs work which you're going to need to the to go to the fda the other side of it is is the legality
of it and what we have for studying psilocybin is we have 38 section j exemptions to study psilocybin and its analogs and contextually there's probably 45 to 50 of these in canada and we have 38 of them so we can look at psilocybin we can look at silicon we can look at 36 of the other analogs and decide which one is best who's to say for example that psilocybin is the best the chemical
formulation of psilocybin is the best one and what we're looking at are all 38 so we have our models set up we have the ability to look at various diseases and that may sound like a a little bit trivial but to try and set up a model about alzheimer's disease to try and set up a model about depression and when i say a model i'm talking about animal models
to try and do that is actually takes a lot to get a most with alzheimer's disease or an animal with alzheimer's disease takes a couple of years and our research has been going on our researchers have been looking at this gene for 10 years this is not something that we just decide oh this sounds good let's do it the neuro inflammatory part has come on in the last two or three years but we've
actually have models that show that and this is going to sound you know very researchy scientific ease of my apologies but we have it so that a depressed mouse gets better and the answer is to your next question is yes you can tell the most is depressed because they stopped eating this stuff going through mazes all of these things and they're humanized mice so they tend to extrapolate
through to the humans is is you know in the majority of time we're looking at a lot of different models one of them one of the things that our research team did as well which was back in september is they actually had an article published in the lancet and barrington you may or may not know but lance it's probably the number one medical journal in the world no no i didn't know how do you how do
you spell that l-a-n-c-e-t lancet take a look if you're if you're listening and watching yeah it's dr wilford jeffries is our chief researcher and their article is quite amazing because in in the models that we have they have actually shown that alzheimer's disease can regress and that's not hold still does not slow down that's get better and what you saw was in the animal models that the animals actually started
remembering things again and that's truly astounding albeit it wasn't with psilocybin it was with another it was with an older anti-cancer drug but psilocybin has the same properties so that's why we're studying and we have patents and that's why we're looking at that with relation to alzheimer's when we do this barrington we don't simply go in and say well let's try it there's a lot of scientific work and
data and research before we attempt this and what we've seen is pretty amazing well that is a that is a massive differentiator no it's it's incredible and like i said we we truly hope that this this carries forward quality of life is is paramount now i know you're not by yourself at mind life sciences again ticker symbol m-y-n-d can you give a shout-out to a couple
members of your team yeah absolutely dr wilf jeffries is our chief researcher and wilf is truly an amazing man he has over 60 patents he's been published over a hundred times he's truly one of these guys who is a energetic researcher another lady that has come on with us is a lady by the name of dr irina ceranovich and she is a phd md
and that's a very rare combination but she is leading our clinical trials and designing our clinical trials so between those two people right there and myself by the way i you know i've got to put in a plug for myself too bearing oh absolutely last but not least either for new investors and for current investors what do they have to look forward to with my life sciences
in the near and mid future sure one of the issues with any research and development company is i mentioned the a to b to c to d and there is a regimented you know formula that you have to go through and that takes some time so typically with an r d company you're looking at revenue being down the road there's two things i want to comment on
that first of all research has changed and one of the important elements of it that is changing is actually artificial intelligence ai because what ai has done is taken a a algorithms that used to used to take a million different molecules and bring it down to three or four it would take years and years for scientists to do that well now we're talking you know days and weeks in order
to do that with artificial intelligence artificial intelligence has changed the research and development scene considerably especially as it applies to new drugs and new medications so we're using ai to a significant degree and it will speed up dramatically what we're doing excuse me the second point that i wanted to mention is the biomarker so we think and our biomarker will be ready to be commercialized in q2 of this
coming year and we think that this is going to be huge from several points of view first of all when it comes to research and development to give people an objective marker of what their their product is actually doing is huge whether it's from you know iv ketamine whether it's from you know visual booths whether it's from anything that has been out there to see that depression and
neuro neurologic illnesses are getting better to have an objective marker obviously is huge so that's one side of it but we also think that there's an element of overall inflammation in the body and we think that this marker may well have an ability to track your particular inflammatory processes in the body and we think that we'll be able to show when you're having a you know when inflammation is rising when inflammation
is decreasing which may actually be able to tell you whether or not some of these medications these natural health products that you're taking are actually working on behalf of the cse we appreciate you dr lyle for taking the time to explain exactly what mind life sciences does and the direction that it's heading in and where it was coming from please continue to stay healthy and safe
for those of you who enjoy this interview and who are listening and watching you can find out more on www.thecsc.com also check out the social usual social media channels instagram facebook linkedin and twitter and with that we are concluding our interview with dr lyle olberg ceo of mind life sciences symbol my nd training on the csc thank you have a happy holidays and stay safe thank you for tuning in to another newly
listed on the csc please feel free to hit like and share this content and hit subscribe if you haven't already



